Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac Effects of BI 409306 in Healthy Males
NCT02438683Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of osoresnontrine in Alzheimer's disease (AD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Slope of the Placebo-corrected Change From Baseline of Heart Rate at Rest and Plasma Concentration up to 10 hours and Maximum Difference to Placebo of the Change From Baseline in Heart Rate at Rest up to 4 hours. Started May 2015; status: completed.
02
Drugs
osoresnontrine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02438683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02438683.